Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Real Estate · CIK 0001492298
$19.60
+3.70% · live
Updated
$4.93B market value
From Sabra Health Care REIT, Inc.'s FY2025 10-K, filed Feb 12, 2026 · read the filing
Sabra Health Care REIT owns income-producing property as a REIT. It took in $356.9M last year, which makes it a smaller company. Of every dollar it sells, about 44 cents is left as profit.
The financial picture is led by profitability and growth, with debt worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
Strong finances across the board.
From Sabra Health Care REIT, Inc.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Revenue
$284.6M → $356.9M
Profit
$126.7M → $155.6M
Earnings per share
$0.53 → $0.62
Cash
$60.5M → $71.5M
Measured against FY2024, from the 10-K filed Feb 12, 2026
Improved: +25.4%
$284.6M to $356.9MSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
How the latest move compares (quote live), and what was published around it
SBRA rose 3.70% on the latest quote. The average Real Estate company tracked here moved +1.90%, and the S&P 500 −1.04%. That is 1.8 points above its sector and 4.7 points above the market.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 23 analysts covering this company, as of . Their views, not this site's.
Of 23 analysts publishing on this company, 4 say strong buy, 8 say buy and 11 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 44 cents of every dollar of sales as profit, earning $155.6M last year.
Yes, quickly. Sales grew 25.4% last year.
For every $1 it owes, it owns $2.06 in assets. Banks and insurers always carry high debt — that is how lending works — so this is normal for the industry and not comparable with other sectors.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 186% of its profit. Property trusts are required to distribute most of their income and report profit after heavy depreciation, so a figure above 100% is normal here rather than a warning. It paid out 83% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $155.6M and generated $348.6M of cash from operations.
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 12, 2026Filing for FY2025 | FY202410-K · Feb 19, 2025Filing for FY2024 | FY202310-K · Feb 27, 2024Filing for FY2023 | FY202210-K · Feb 21, 2023Filing for FY2022 | FY202110-K · Feb 22, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $356.9M | $284.6M | $236.2M | $186.7M | $155.5M | +25.4% |
| Selling, general and administrative | $53.7M | $50.1M | $47.5M | $39.6M | $34.7M | +7.3% |
| Interest expense | $112.5M | $115.3M | $113.0M | $105.5M | $98.6M | −2.4% |
| Income before tax | $153.4M | $128.1M | $18.7M | $21.7M | $80.7M | +19.8% |
| Net income | $155.6M | $126.7M | $13.8M | -$77.6M | -$113.3M | +22.8% |
| Net marginNet income ÷ revenueWhat is this? | 43.6% | 44.5% | 5.8% | -41.6% | -72.8% | −0.9 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $0.6182 | $0.5333 | $0.0595 | $-0.3359 | $-0.4916 | +15.9% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| SBRASabra Health Care REIT, Inc. · this page | 8.7/10 | 5/7 | 25.4% | 43.6% | 31.70x | 0.95x |
| AREALEXANDRIA REAL ESTATE EQUITIES, INC. | 3.3/10 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 200,000 shares at $20.83 ($4.2M)
Holds 1,657,686 shares after this filing.
Was granted or awarded shares — 791 shares
Holds 54,580 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q2 FY2026
Revenue +63.1% · Profit margin −102.6 pts · Profit turned negative — against Q2 FY2025
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingWrite down why you are following Sabra Health Care REIT, Inc., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 388 subsidiaries named in its 10-K, incorporated across 10 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from SBRA's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 12, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 7 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 8.7 | 5/7 | 10-K, filed Feb 12, 2026 |
| FY2024 | 8.7 | 5/7 | 10-K, filed Feb 19, 2025 |
| FY2023 | 7.3 | 6/7 | 10-K, filed Feb 27, 2024 |
| FY2022 | 6.0 | 5/7 | 10-K, filed Feb 21, 2023 |
| FY2021 | 3.3 | 2/7 | 10-K, filed Feb 22, 2022 |
| FY2020 | 8.7 | 5/7 | 10-K, filed Feb 22, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
5 of 7 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. 2 could not be evaluated and are excluded from the total rather than counted as failures.
not reported — Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +22.8%
$126.7M to $155.6MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +15.9%
$0.53 to $0.62Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +18.3%
$60.5M to $71.5MSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: +5.9%
237.6M to 251.7MSignificant
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 3, 2026 — read it.
Improved: +63.1%
$79.0M to $128.8MCritical
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: turned negative
$65.5M to -$25.2MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −102.6 pts
83.0% to -19.6%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: turned negative
$0.27 to -$0.10Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +143.3%
$95.2M to $231.6MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: +6.5%
239.8M to 255.5MSignificant
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Deteriorated: +5.9%
$2.48B to $2.63BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 3, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: turned negative
$40.9M to -$25.2MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −54.6 pts
35.0% to -19.6%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: turned negative
$0.16 to -$0.10Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +98.7%
$116.5M to $231.6MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +10.4%
$116.7M to $128.8MNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: +1.3%
252.2M to 255.5MNotable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 7.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 47.5x — a high multiple relative to the current trailing profit.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Reported annual figures
| 4/7 |
| -2.9% |
| -47.2% |
| — |
| 0.96x |
| Median of peers | 3.3/10 | — | -2.9% | -47.2% | — | 0.96x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Was granted or awarded shares — 791 shares
Holds 82,847 shares after this filing.
Was granted or awarded shares — 791 shares
Holds 82,834 shares after this filing.
Was granted or awarded shares — 791 shares
Holds 86,912 shares after this filing.
Was granted or awarded shares — 791 shares
Holds 68,977 shares after this filing.
Was granted or awarded shares — 791 shares
Holds 117,137 shares after this filing.
Was granted or awarded shares — 495 shares
Holds 116,919 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 200,000 shares ($4.2M) on or after .
Shares originally obtained via Restricted Stock Units.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Made a Regulation FD disclosure
Held a shareholder vote
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q1 FY2026
Revenue +50.7% · Profit margin −17.0 pts · Cash +414.4% — against Q1 FY2025
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Revenue +25.4% · Profit +22.8% · Earnings per share +15.9% — against FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Revenue +24.8% · Profit margin −15.9 pts · Cash +218.4% — against Q3 FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingSigned a material agreement · Terminated a material agreement
Read the filingQuarterly report for Q2 FY2025
Revenue +16.3% · Profit margin +47.7 pts · Profit +173.4% — against Q2 FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingSigned a material agreement · Took on a direct financial obligation · Reported another event
Read the filingReported another event
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2025
Revenue +17.3% · Profit margin +12.3 pts · Profit +53.5% — against Q1 FY2024
Read the filingThe first 40 of 388. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-12. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
PEB vs. SBRA: Which Stock Is the Better Value Option?
Yahoo ·
Sabra Health Care REIT, Inc. Announces Third Quarter 2026 Earnings Release Date and Conference Call
Yahoo ·
Wells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21
Benzinga ·
UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20
Benzinga ·
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21
Benzinga ·
Omega Healthcare: Attractive For The Near 6% Yield, But Don't Expect Meaningful Upside (Rating Downgrade)
SeekingAlpha ·
Primary sources and further research